A Phase I Safety and Immunogenicity Trial of MVA-BN-HER2 Vaccine in Locally Advanced and Advanced HER2+ Breast Cancer (GENE TRANSFER PROTOCOL).

Trial Profile

A Phase I Safety and Immunogenicity Trial of MVA-BN-HER2 Vaccine in Locally Advanced and Advanced HER2+ Breast Cancer (GENE TRANSFER PROTOCOL).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2011

At a glance

  • Drugs MVA BN HER2 (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors BN ImmunoTherapeutics
  • Most Recent Events

    • 10 Dec 2010 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 Jul 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top